TITLE

Therapeutic Potential of Docetaxel plus Cisplatin Chemotherapy for Myasthenia Gravis Patients with Metastatic Thymoma

AUTHOR(S)
Guoyan Qi; Peng Liu; Huimin Dong; Shanshan Gu; Hongxia Yang; Yinping Xue
PUB. DATE
April 2017
SOURCE
Tohoku Journal of Experimental Medicine;Apr2017, Vol. 241 Issue 4, p281
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The prognosis of myasthenia gravis (MG) in association with invasive or metastatic thymoma is usually worse, and therapeutic options are quite limited. Here, we retrospectively reported the therapeutic effect of docetaxel plus cisplatin (docetaxel/cisplatin) chemotherapy in 7 MG patients with metastatic thymoma. Previously, all patients underwent thymectomy at the first onset of thymoma. After the metastasis of thymoma, none of the patients received thymectomy due to unresectable conditions after surgeon's evaluation for great risk of myasthenic crisis (n = 5) or patients' refusal (n = 2). All patients received docetaxel (75 mg/m2) and cisplatin (70 mg/m2) on day 1 (d1) every 21 days, with the cycle ranging from 1 to 4. After docetaxel/cisplatin chemotherapy, one patient achieved partial response, and 6 with stable disease of the tumors. The clinical symptoms of MG were alleviated in all patients, 2 with complete remission and the other 5 with marked improvement. Myelosuppression was the major adverse event, occurring in 2 patients (grade II and IV). MG relapse occurred in one patient during the follow-up. Our study presented a series of MG patients with metastatic thymoma who underwent docetaxel/cisplatin chemotherapy. Besides the improved/stabilized thymoma, markedly improvement of MG with the tolerable adverse events was achieved. Docetaxel/cisplatin chemotherapy appears to be an effective treatment for selected patients with MG in association with unresectable metastatic thymoma. Further follow-up of these patients and additional subjects will be needed to determine whether the therapeutic benefits are durable.
ACCESSION #
122468777

 

Related Articles

  • Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity. Callizot, Noelle; Andriambeloson, Emile; Glass, Jonathan; Revel, Michel; Ferro, Pamela; Cirillo, Rocco; Vitte, Pierre-Alain; Dreano, Michel // Cancer Chemotherapy & Pharmacology;Nov2008, Vol. 62 Issue 6, p995 

    This study was conducted to investigate the potential neuroprotective effect of IL-6 on chemotherapy induced neuropathy (CIN). IL-6 was compared to four-methylcatechol (4-MC)-a known inducer of NGF secretion previously shown to exhibit neuroprotective effects in CIN models. Three CIN models were...

  • Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Chiarion-Sileni, V.; Corti, L.; Ruol, A.; Innocente, R.; Boso, C.; Del Bianco, P.; Pigozzo, J.; Mazzarotto, R.; Tomassi, O.; Ancona, E. // British Journal of Cancer;2/12/2007, Vol. 96 Issue 3, p432 

    This study was performed to assess the efficacy and safety of docetaxel, cisplatin and fluorouracil combination in patients with unresectable locally advanced oesophageal squamous cell carcinoma. Treatment consisted of docetaxel 60 mg m−2, cisplatin 75 mg m−2 on day 1 and...

  • Cisplatin/docetaxel/fluorouracil.  // Reactions Weekly;7/10/2010, Issue 1309, p17 

    The article describes the case of a 69-year-old man who developed multiple Beau's lines on his fingernails while under cisplatin, docetaxel and fluorouracil chemotherapy regimen for gastric cancer.

  • POINT/COUNTER. Shah, Manish A.; Moss, Rebecca A. // Hem/Onc Today;2/25/2008, Vol. 9 Issue 3, p11 

    The article presents a response to a question about adding docetaxel to cisplatin and 5-FU in gastric cancer.

  • Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study. Nardi, Mario; de Marco, Salvatore; Fabi, Alessandra; Aloe, Alessandra; Magnani, Elena; Pacetti, Umberto; Carlini, Paolo; Ruggeri, Enzo Maria; Cognetti, Francesco; Nardi, M; De Marco, S; Fabi, A; Aloe, A; Magnani, E; Pacetti, U; Carlini, P; Ruggeri, E M; Cognetti, F // Cancer Chemotherapy & Pharmacology;Sep2001, Vol. 48 Issue 3, p255 

    Purpose: The combination of paclitaxel and cisplatin is considered the standard regimen for advanced ovarian cancer (AOC). A meta-analysis has shown that the incorporation of anthracyclines into first-line chemotherapy might improve long-term survival by 7-10%. We designed a phase...

  • Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer. Jung Hye Kwon; Jung Han Kim; Jung-Ae Lee; Hyun Chun Shin; Hyo Jung Kim; Hun Ho Song; Joo Young Jung; Ho Young Kim; Dae Ro Choi; Hyeong Su Kim; Young-iee Park; Dae Young Zang // Cancer Chemotherapy & Pharmacology;Oct2010, Vol. 66 Issue 5, p889 

    Docetaxel and cisplatin combination chemotherapy is established first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). We evaluated a weekly schedule of docetaxel and cisplatin for efficacy and tolerability in patients with chemotherapy-naive NSCLC. Patients enrolled in this...

  • Cisplatin/docetaxel/fluorouracil.  // Reactions Weekly;May2015, Vol. 1549 Issue 1, p71 

    The article presents a case study of a patient with fatal infection after administration of the drugs cisplatin, docetaxel and fluorouracil.

  • Cisplatin/docetaxel/fluorouracil.  // Reactions Weekly;8/31/2013, Issue 1467, p11 

    The article discusses the case report of a 56-year-old man who developed haemophagocytic lymphohistiocytosis (HLH) leading to refractory shock after receiving cisplatin, docetaxel and fluorouracil.

  • Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Garcia del Muro, X.; Marcuello, E.; Guma, J.; Paz-Ares, L.; Climent, M.A.; Carles, J.; Parra, M. Sanchez; Tisaire, J.L.; Maroto, P.; Gema, J.R. // British Journal of Cancer;2/1/2002, Vol. 86 Issue 3, p326 

    A multicentre phase II trial was undertaken to evaluate the activity and toxicity of docetaxel plus cisplatin as first-line chemotherapy n patients with urothelial cancer. Thirty-eight patients with locally advanced or metastatic transitional-cell carcinoma of the bladder, renal pelvis or ureter...

  • Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. Haddad, Robert I.; Van Echo, David A. // Cancer Chemotherapy & Pharmacology;Oct2003, Vol. 52 Issue 4, p303 

    Purpose. To evaluate the activity of combination chemotherapy with docetaxel and topotecan in patients with advanced head and neck cancer. Methods. Docetaxel was given at 60 mg/m2 as a 60-min intravenous infusion on day 1. Topotecan at 0.75 mg/m2 per day was infused over 30 min on days 1, 2 and...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics